Culture Biosciences
We grow cells for biotech companies.
South San Francisco, United States · Founded 2016 · $100.5M raised
- Headquarters
- South San Francisco, California
- Employees
- 11–50
- Founded
- 2016
- Business Model
- B2B
- Website
- culturebiosciences.com
- Total Funding
- $100.5M
- Last Round
- $80.0M Series CDec 2025
- Rounds
- 4
About
Culture Biosciences grows cells for biotech companies. Our customers genetically modify organisms to produce new therapeutics, materials, fuels and foods. We help them quickly run experiments and develop manufacturing processes so they can get their products to market faster. We've built proprietary software and automation systems to make operating our bioreactors more efficient than existing systems. We also provide customers with new software tools that help them analyze and contextualize their data. We are currently serving a number of biotech customers and scaling out our infrastructure.
Summary
Culture Biosciences is an Agtech company based in South San Francisco, United States, founded in 2016. It has raised $100.5M in total across 4 rounds, most recently a $80.0M Series C round in Dec 2025. Investors include Cultivian Sandbox Ventures, Section 32 and Northpond Ventures.
Tech & App Stack
5 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2025
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...

Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.

Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...


